Opsona Therapeutics

Opsona Therapeutics was a drug development company specialising in the human immune system and new drugs and vaccines to prevent and treat autoimmune/inflammatory conditions, cancers and infectious diseases.[1][2][3]

Opsona Therapeutics
Headquarters
Dublin 
,
Republic of Ireland 
Websitewww.opsona.com

Based in Ireland, Opsona was a spin-out from Trinity College Dublin (TCD).[4] Ireland is ranked highly in the world in immunology research, and TCD has been at the forefront of the field.[5]

Opsona's research was primarily focused on the role of Toll-like receptors (TLRs) and TLR signalling in human innate immunity. The company was founded in 2004 by three immunologists:

The company went into liquidation in 2019 after unsuccessful clinical trials and failure to find a buyer for OPN-305.

Opsona's main investors were international and life-science focused:

  • Inventages Venture Capital (Bahamas)[9]
  • Seroba Bioventures (Ireland)
  • GenenFund (United States)
  • Enterprise Ireland (Ireland)[10]

References
  1. "Ireland's got talent". Retrieved 27 February 2018.
  2. "Sunday Business Post article". Retrieved 27 February 2018.
  3. "Opsona Therapeutics Limited: Private Company Information - Bloomberg". investing.businessweek.com. Retrieved 27 February 2018.
  4. "Emerging finalist: Mark Heffernan Opsona Therapeutics". Retrieved 27 February 2018.
  5. Times Higher Educational Supplement - QS World University Rankings 2007
  6. "Trinity team makes vaccine discovery". 4 May 2009. Retrieved 27 February 2018.
  7. Dublin, bbutler@tcd.ie, Trinity College. "Kingston Mills - Research : School of Biochemistry and Immunology : Trinity College Dublin, the University of Dublin, Ireland". www.tcd.ie. Retrieved 27 February 2018.
  8. "Article on the Trinity College Dublin website". Retrieved 27 February 2018.
  9. "Opsona Therapeutics Closes EUR18M Funding - FierceBiotech". www.fiercebiotech.com. Retrieved 27 February 2018.
  10. "PR Newswire article". Retrieved 27 February 2018.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.